These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. 18F-fluorodeoxyglucose (FDG) PET/CT after two cycles of neoadjuvant therapy may predict response in HER2-negative, but not in HER2-positive breast cancer. Cheng J; Wang Y; Mo M; Bao X; Zhang Y; Liu G; Zhang J; Geng D Oncotarget; 2015 Oct; 6(30):29388-95. PubMed ID: 26336821 [TBL] [Abstract][Full Text] [Related]
3. Baseline Tumor 18F-FDG Uptake and Modifications After 2 Cycles of Neoadjuvant Chemotherapy Are Prognostic of Outcome in ER+/HER2- Breast Cancer. Groheux D; Sanna A; Majdoub M; de Cremoux P; Giacchetti S; Teixeira L; Espié M; Merlet P; de Roquancourt A; Visvikis D; Hatt M; Resche-Rigon M; Hindié E J Nucl Med; 2015 Jun; 56(6):824-31. PubMed ID: 25883123 [TBL] [Abstract][Full Text] [Related]
4. Subtype-Guided Wu S; Wang Y; Li J; Zhang N; Mo M; Klimberg S; Kaklamani V; Cochet A; Shao Z; Cheng J; Liu G Oncologist; 2020 Apr; 25(4):e626-e633. PubMed ID: 32297448 [TBL] [Abstract][Full Text] [Related]
5. Monitoring tumor response to neoadjuvant chemotherapy using MRI and 18F-FDG PET/CT in breast cancer subtypes. Schmitz AMT; Teixeira SC; Pengel KE; Loo CE; Vogel WV; Wesseling J; Rutgers EJT; Valdés Olmos RA; Sonke GS; Rodenhuis S; Vrancken Peeters MJTFD; Gilhuijs KGA PLoS One; 2017; 12(5):e0176782. PubMed ID: 28531188 [TBL] [Abstract][Full Text] [Related]
6. Combination of breast imaging parameters obtained from Grapin M; Coutant C; Riedinger JM; Ladoire S; Brunotte F; Cochet A; Humbert O Eur J Radiol; 2019 Apr; 113():81-88. PubMed ID: 30927964 [TBL] [Abstract][Full Text] [Related]
7. HER2-positive breast cancer: ¹⁸F-FDG PET for early prediction of response to trastuzumab plus taxane-based neoadjuvant chemotherapy. Humbert O; Cochet A; Riedinger JM; Berriolo-Riedinger A; Arnould L; Coudert B; Desmoulins I; Toubeau M; Dygai-Cochet I; Guiu S; Coutant C; Fumoleau P; Brunotte F Eur J Nucl Med Mol Imaging; 2014 Aug; 41(8):1525-33. PubMed ID: 24647576 [TBL] [Abstract][Full Text] [Related]
8. Biomarkers from in vivo molecular imaging of breast cancer: pretreatment Gallivanone F; Panzeri MM; Canevari C; Losio C; Gianolli L; De Cobelli F; Castiglioni I MAGMA; 2017 Aug; 30(4):359-373. PubMed ID: 28246950 [TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant chemotherapy in breast cancer: prediction of pathologic response with PET/CT and dynamic contrast-enhanced MR imaging--prospective assessment. Tateishi U; Miyake M; Nagaoka T; Terauchi T; Kubota K; Kinoshita T; Daisaki H; Macapinlac HA Radiology; 2012 Apr; 263(1):53-63. PubMed ID: 22438441 [TBL] [Abstract][Full Text] [Related]
10. Groheux D; Martineau A; Teixeira L; Espié M; de Cremoux P; Bertheau P; Merlet P; Lemarignier C Breast Cancer Res; 2017 Jan; 19(1):3. PubMed ID: 28057031 [TBL] [Abstract][Full Text] [Related]
11. PET/CT radiomics in breast cancer: promising tool for prediction of pathological response to neoadjuvant chemotherapy. Antunovic L; De Sanctis R; Cozzi L; Kirienko M; Sagona A; Torrisi R; Tinterri C; Santoro A; Chiti A; Zelic R; Sollini M Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1468-1477. PubMed ID: 30915523 [TBL] [Abstract][Full Text] [Related]
12. Complete Metabolic Response on Interim Chen S; Ibrahim NK; Yan Y; Wong ST; Wang H; Wong FC Oncologist; 2017 May; 22(5):526-534. PubMed ID: 28377466 [TBL] [Abstract][Full Text] [Related]
13. Utility of Lee IH; Lee SJ; Lee J; Jung JH; Park HY; Jeong SY; Lee SW; Chae YS BMC Cancer; 2020 Nov; 20(1):1106. PubMed ID: 33198673 [TBL] [Abstract][Full Text] [Related]
14. Additional value of van Ramshorst MS; Teixeira SC; Koolen BB; Pengel KE; Gilhuijs KG; Wesseling J; Rodenhuis S; Valdés Olmos RA; Rutgers EJ; Vogel WV; Sonke GS; Vrancken Peeters MT Cancer Imaging; 2017 May; 17(1):15. PubMed ID: 28545563 [TBL] [Abstract][Full Text] [Related]
15. FDG PET/CT during neoadjuvant chemotherapy may predict response in ER-positive/HER2-negative and triple negative, but not in HER2-positive breast cancer. Koolen BB; Pengel KE; Wesseling J; Vogel WV; Vrancken Peeters MJ; Vincent AD; Gilhuijs KG; Rodenhuis S; Rutgers EJ; Valdés Olmos RA Breast; 2013 Oct; 22(5):691-7. PubMed ID: 23414930 [TBL] [Abstract][Full Text] [Related]
16. The Value of Semiquantitative Parameters Derived from Urso L; Evangelista L; Alongi P; Quartuccio N; Cittanti C; Rambaldi I; Ortolan N; Borgia F; Nieri A; Uccelli L; Schirone A; Panareo S; Arnone G; Bartolomei M Cancers (Basel); 2022 Nov; 14(23):. PubMed ID: 36497351 [TBL] [Abstract][Full Text] [Related]
17. Tumor metabolism assessed by FDG-PET/CT and tumor proliferation assessed by genomic grade index to predict response to neoadjuvant chemotherapy in triple negative breast cancer. Groheux D; Biard L; Lehmann-Che J; Teixeira L; Bouhidel FA; Poirot B; Bertheau P; Merlet P; Espié M; Resche-Rigon M; Sotiriou C; de Cremoux P Eur J Nucl Med Mol Imaging; 2018 Jul; 45(8):1279-1288. PubMed ID: 29616304 [TBL] [Abstract][Full Text] [Related]
18. FDG-PET/CT and MRI for Evaluation of Pathologic Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer: A Meta-Analysis of Diagnostic Accuracy Studies. Sheikhbahaei S; Trahan TJ; Xiao J; Taghipour M; Mena E; Connolly RM; Subramaniam RM Oncologist; 2016 Aug; 21(8):931-9. PubMed ID: 27401897 [TBL] [Abstract][Full Text] [Related]
19. Textural features of Cheng L; Zhang J; Wang Y; Xu X; Zhang Y; Zhang Y; Liu G; Cheng J Ann Nucl Med; 2017 Aug; 31(7):544-552. PubMed ID: 28646331 [TBL] [Abstract][Full Text] [Related]
20. Predictive Value of Song BI; Kim HW; Won KS Ann Surg Oncol; 2017 Aug; 24(8):2174-2181. PubMed ID: 28432480 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]